AIM IP specialist Tekcapital to sell or float all four portfolio companies 'within 2 years'. Watch the full video here

Less Ads, More Data, More Tools Register for FREE

Fifteen scientists launch critique of Russia's COVID-19 vaccine data

Mon, 14th Sep 2020 18:58

By Emilio Parodi

MILAN, Sept 14 (Reuters) - A group of scientists sent a
formal letter to the Lancet on Monday outlining doubts about the
accuracy of early data on Russia's COVID-19 vaccine, one of the
authors said, adding further fuel to a dispute surrounding the
"Sputnik-V" shot.

Fifteen scientists from five countries signed the letter
presenting their concerns to the international medical journal,
Enrico Bucci, biologist adjunct professor at Philadelphia's
Temple University, told Reuters.

Reuters did not see the contents of the letter. The move
nonetheless highlights growing concern among scientists about
the safety and efficacy of the Sputnik-V vaccine, which the
government approved for use before completing full human trials.

The official letter came days after a larger group of
scientists - including the 15 - signed an open letter to the
Lancet's editor, published on Bucci's personal blog, after the
journal published the early-stage trial results from Moscow's
Gamaleya Institute.

They said they found patterns in the Phase I/II data, which
was peer-reviewed in the journal, that looked "highly unlikely",
with multiple participants reporting identical antibody levels.

The Gamaleya Institute did not immediately respond to a
request for comment about the formal letter sent on Monday.

Last week the institute rejected the critique contained in
the open letter, which was initially signed by 26 scientists but
now has 38 signatories.

"The published results are authentic and accurate and were
examined by five reviewers at The Lancet," Denis Logunov, a
deputy director at the institute, said in a statement.

He said his institute submitted the entire body of raw data
on the trial results to The Lancet.

The Lancet said it had invited the authors of the Russian
vaccine study to respond to the questions raised in the open
letter by Bucci.

"We continue to follow the situation closely," it added.

Alexey Kuznetsov, Russian assistant health minister, told
the Interfax news agency on Sept. 10 that the Gamaleya Institute
had already sent detailed answers to the Lancet's editor.


Bucci said the blog published last week had drawn wide
international support.

"We started with about a dozen of us and now we have reached
three times the signatures, with colleagues from the United
States, Switzerland, Australia, India, Russia, Great Britain,
Japan, Germany, Canada," Bucci said.

He said the formal letter to the Lancet was signed only by
15 scientists with expertise in virology, immunology,
pharmaceutical development, research integrity and statistical
analysis. Most were Italian, but they also included scientists
from Sweden, Britain, the United States and Japan, he added.

"The journal's editor wrote asking us to send him our points
of objections and inviting the authors of Russian vaccine's
study to respond to our points," said Bucci.

Naor Bar-Zeev, deputy director at John Hopkins Bloomberg
School of Public Health, who peer-reviewed the Russian data,
last week defended his analysis of the research following the
publication of the blog.

"The results are plausible, and not very different to those
seen with other AdV vectored products," he said.

The researchers had provided more detail than was needed for
the review and responded to his questions "intelligently and in
a matter-of-fact and confident but understated manner".

The results of the Russian Phase I/II trials, which involved
76 participants and was conducted in June-July, were published
in the Lancet on Sept. 4. They showed that participants
developed a positive immune response and no serious side
effects, the study's authors said.

A Phase III trial, involving 40,000 participants, was
launched on Aug. 26. Around 31,000 people have already
subscribed to take part, Health Minister Mikhail Murashko said.

(Reporting by Emilio Parodi; Editing by Josephine Mason and
Pravin Char)

More News

PRESS: Rolls-Royce restarts Bergen sale process after Norway veto

PRESS: Rolls-Royce restarts Bergen sale process after Norway veto

Today 20:18

LIVE MARKETS-Q1 profits continue to leapfrog expectations

* Major U.S. indexes rise; Nasdaq leads with gain of ~0.7%* All major S&P sectors higher: Energy leads* Dollar down; gold rises; crude edges higher* U.S. 10-Year Treasury yield fell to low of 1.4690%, now ~1.58%May 7 - Welcome to the home for real-t...

Today 19:57

DIRECTOR DEALINGS: Ocado Non-Exec Rausing buys GBP26 million worth

DIRECTOR DEALINGS: Ocado Non-Exec Rausing buys GBP26 million worth

Today 19:36

IN BRIEF: DP Aircraft shares jump on deal with Thai lenders

IN BRIEF: DP Aircraft shares jump on deal with Thai lenders

Today 19:32

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.